Protocol Ledger

NCT04562389 · Phase III · ACTIVE NOT RECRUITING

Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis

Interventional Phase III clinical trial protocol NCT04562389 sponsored by Karyopharm Therapeutics in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-03-11 Enrollment: 353 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04562389
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)353 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04562389
Protocol FieldVerified Registry Value
NCT IdentifierNCT04562389
Consolidated Lead SponsorKaryopharm Therapeutics
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment353 participants (ACTUAL)
Registered Start Date2021-03-11
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI